No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Caplin Point Laboratories Limited is a pharmaceutical firm actively involved in the development, manufacture, marketing, and export of both generic medications and proprietary branded products, primarily operating within India. Their extensive product portfolio encompasses a broad spectrum of pharmaceutical dosage forms, including various types of injections (liquid, lyophilized, IV infusions, powder for injection), oral preparations (tablets, liquid orals, capsules, softgel capsules, dry syrups), specialized applications (ophthalmic products, suppositories and ovules), and topical treatments (topicals, dermo cosmetics, inhalers). Beyond manufacturing, the company also manages an e-commerce platform named QueTenX. Established in 1990, Caplin Point Laboratories maintains its headquarters in Chennai, India.
www.caplinpoint.netNo one on the platform currently holds CAPLIPOINT.NS.
No tracked institution reports a position in CAPLIPOINT.NS as of their last filing.
No one on the platform has traded CAPLIPOINT.NS yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 18.7% | 30.5% | 43.6% | — | — | — |
| Rev. Growth % | 12.8% | 15.5% | ||||
| Profit Margin % | 29.3% | 26.6% | 25.9% | |||
| Free Cash Flow Margin % | 15.4% | 12.5% | 9.4% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $25.0B | +17.5% | $97.00 | $95.58–$98.42 | — | 2 |
| 2028 | $28.1B | +12.4% | $112.10 | $110.68–$113.52 | — | 2 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| CAPLIPOINT.NSCaplin Point Laboratories Limited | $2570.60 | -6.69% | $195.4B | — |
| APLLTD.BOAlembic Pharmaceuticals Limited | $822.40 | +1.47% | $161.6B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited | $824.75 | +1.70% | $162.1B | — |
| CONCORDBIO.BOConcord Biotech Limited | $1471.50 | -2.33% | $154.2B | — |
| CONCORDBIO.NSConcord Biotech Limited | $1473.00 | -2.17% | $154.1B | — |
| GRANULES.BOGranules India Limited | $872.50 |
Source: Financial Modeling Prep · peers by sector/industry
| -4.08% |
| $217.2B |
| — |
| GRANULES.NSGranules India Limited | $872.60 | -4.04% | $216.2B | — |